GlassScriptPhysician profile
Philippe I Bulauitan
NPI 1609168988
$5,493.95
in general payments reported to CMS, 2019-2025
34 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $325 · 2021: $1,050 · 2022: $797 · 2023: $1,075 · 2024: $951 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,847.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,142.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $724.46 | 2019-2025 | Yeztugo |
| Abbvie INC. | $647.75 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $602.39 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $371.01 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $363.92 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $276.54 | 2019-2025 | |
| Viiv Healthcare Company | $160.49 | 2022-2025 | Apretude |
| Adlon Therapeutics L.P. | $132.69 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $113.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.00 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $92.00 | 2021 | |
| Amarin Pharma, INC. | $80.94 | 2021 | |
| Abbott Laboratories | $73.73 | 2024-2025 | Lamitrode, Eterna, Octrode |
| Teva Pharmaceuticals USA, INC. | $65.03 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.43 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $51.01 | 2020-2022 | |
| Genentech USA, INC. | $49.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.12 | 2019-2021 | |
| Amgen INC. | $41.50 | 2019-2025 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $38.33 | 2021-2023 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $38.33 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $37.45 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.90 | 2024-2025 | Xifaxan |
| Sanofi Pasteur INC. | $23.25 | 2019 | |
| Boston Scientific Corporation | $22.47 | 2025 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $18.93 | 2025 | Cologuard Collection Kit |
| Optos, INC. | $17.73 | 2020 | |
| Hologic Sales and Service, LLC | $17.71 | 2023 | Thinprep 2000 Processor |
| Shire North American Group INC | $15.07 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.84 | 2024 | Caplyta |
| Esperion Therapeutics, INC. | $12.86 | 2021 | |
| Phadia US INC. | $12.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Bulauitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.